These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 8319212)
1. Anticancer efficacy of Magainin2 and analogue peptides. Baker MA; Maloy WL; Zasloff M; Jacob LS Cancer Res; 1993 Jul; 53(13):3052-7. PubMed ID: 8319212 [TBL] [Abstract][Full Text] [Related]
2. Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo. Guo QL; Wu MS; Chen Z Acta Pharmacol Sin; 2002 Oct; 23(10):946-51. PubMed ID: 12370101 [TBL] [Abstract][Full Text] [Related]
3. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Johnstone SA; Gelmon K; Mayer LD; Hancock RE; Bally MB Anticancer Drug Des; 2000 Apr; 15(2):151-60. PubMed ID: 10901303 [TBL] [Abstract][Full Text] [Related]
4. [Anti-tumor effect of hernandezine and other components extracted from Thalictrum glandulosissimum]. Xu CX; Lin L; Sun RH; Liu X; Han R Yao Xue Xue Bao; 1990; 25(5):330-5. PubMed ID: 2284950 [TBL] [Abstract][Full Text] [Related]
5. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice. Dawson KM Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953 [TBL] [Abstract][Full Text] [Related]
6. Are syngeneic mouse tumor models still valuable experimental models in the field of anti-cancer drug discovery? Darro F; Decaestecker C; Gaussin JF; Mortier S; Van Ginckel R; Kiss R Int J Oncol; 2005 Sep; 27(3):607-16. PubMed ID: 16077908 [TBL] [Abstract][Full Text] [Related]
8. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the antitumor activity of 1-(3-C-ethynyl-beta-D-ribofuranosyl) (PJ272), a recent ribonucleoside analogue. Holl V; Jung P; Weltin D; Dauvergne J; Burger A; Coelho D; Dufour P; Aubertin AM; Bischoff PL; Biellmann JF Anticancer Res; 2000; 20(3A):1739-42. PubMed ID: 10928102 [TBL] [Abstract][Full Text] [Related]
10. Anticancer versus antigrowth activities of three analogs of the growth-inhibitory peptide: relevance to physicochemical properties. Mizejewski GJ; Eisele L; Maccoll R Anticancer Res; 2006; 26(4B):3071-6. PubMed ID: 16886636 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo. Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044 [TBL] [Abstract][Full Text] [Related]
12. [Antitumor activity of macromomycin]. Kato T; Yamanaka N; Katayama S; Mizutani M; Ota K Gan To Kagaku Ryoho; 1982 Jul; 9(6):1097-101. PubMed ID: 7184442 [TBL] [Abstract][Full Text] [Related]
13. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. Tejeda M; Gaál D; Hullán L; Hegymegi-Barakonyi B; Kéri G Anticancer Res; 2006; 26(5A):3477-83. PubMed ID: 17094470 [TBL] [Abstract][Full Text] [Related]
15. Preliminary experimental anticancer activity of cecropins. Moore AJ; Devine DA; Bibby MC Pept Res; 1994; 7(5):265-9. PubMed ID: 7849420 [TBL] [Abstract][Full Text] [Related]
16. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug. Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972 [TBL] [Abstract][Full Text] [Related]
18. Some new aryl-sydnones: effects on murine tumours. Grynberg N; Gomes R; Shinzato T; Echevarria A; Miller J Anticancer Res; 1992; 12(3):1025-8. PubMed ID: 1320354 [TBL] [Abstract][Full Text] [Related]
19. Rational design, synthesis, and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters. Koutsourea AI; Fousteris MA; Arsenou ES; Papageorgiou A; Pairas GN; Nikolaropoulos SS Bioorg Med Chem; 2008 May; 16(9):5207-15. PubMed ID: 18353651 [TBL] [Abstract][Full Text] [Related]
20. Isothiazolopyrimidines--new group of anticancer agents. I. Machoń Z; Wieczorek J; Mordarski M Arch Immunol Ther Exp (Warsz); 1987; 35(5):599-607. PubMed ID: 3455649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]